Benchmarking genome-wide association study causal gene prioritization for drug discovery
Ji, C.; Kerrebijn, I.; Arbabi, K.; Schipper, M.; Wainberg, M.
Show abstract
Drug discovery is costly, with billions spent on failed trials. Drugs with genetic support from genome-wide association studies (GWAS) have substantially greater odds of success, but how best to use GWAS to prioritize drug targets remains unclear. We evaluated the performance of GWAS causal gene prioritization methods from the Open Targets consortium by cross-referencing their predictions with drug trial outcomes for 445 diseases. We found that neither expression quantitative trait locus colocalization nor Open Targets locus-to-gene (L2G) score outperformed the simple nearest gene method at prioritizing which genes would become approved drug targets. Our findings inform the use of genetic evidence in drug discovery.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis 96%
- Multi-layered genetic approaches to identify approved drug targets 96%
- Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases 92%
Similar papers in this journal
Similar papers in this journal
- ADMET-AI: A machine learning ADMET platform for evaluation of large-scale chemical libraries 92%
- Incorporating family disease history and controlling case-control imbalance for population based genetic association studies 92%
- AutoPM3: Enhancing Variant Interpretation via LLM-driven PM3 Evidence Extraction from Scientific Literature 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.